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ABSTRACT
The binding of integrase (IN) to lens epithelium-
derived growth factor (LEDGF)/p75 in large part
determines the efficiency and specificity of HIV-1
integration. However, a significant residual prefer-
ence for integration into active genes persists in
Psip1 (the gene that encodes for LEDGF/p75)
knockout (KO) cells. One other cellular protein,
HRP2, harbors both the PWWP and IN-binding
domains that are important for LEDGF/p75
co-factor function. To assess the role of HRP2 in
HIV-1 integration, cells generated from Hdgfrp2
(the gene that encodes for HRP2) and Psip1/
Hdgfrp2 KO mice were infected alongside matched
control cells. HRP2 depleted cells supported normal
infection, while disruption of Hdgfrp2 in Psip1 KO
cells yielded additional defects in the efficiency
and specificity of integration. These deficits were
largely restored by ectopic expression of either
LEDGF/p75 or HRP2. The double-KO cells neverthe-
less supported residual integration into genes,
indicating that IN and/or other host factors contrib-
ute to integration specificity in the absence of
LEDGF/p75 and HRP2. Psip1 KO significantly
increased the potency of an allosteric inhibitor that
binds the LEDGF/p75 binding site on IN, a result that
was not significantly altered by Hdgfrp2 disruption.
These findings help to rule out the host factor-IN
interactions as the primary antiviral targets of
LEDGF/p75-binding site IN inhibitors.
INTRODUCTION
Reverse transcription of genomic RNA and the subse-
quent integration of viral DNA are essential events in
retroviral replication. The key cutting and joining steps
of the integration reaction are catalysed by the viral-
encoded integrase (IN) and carried out in the context of
the viral preintegration complex (PIC). IN processes the 30
ends of linear viral DNA adjacent to conserved CA di-
nucleotides, and then joins the recessed 30 viral DNA ends
to the 50-phosphates of a staggered cut in chromosomal
DNA (1,2). Cellular enzymes repair the gapped recombin-
ation intermediate to yield the integrated provirus, which
is ﬂanked by a short sequence duplication generated by
the cut in the target DNA. PICs extracted from acutely
infected cells support the integration of retroviral DNA
into exogenous target DNA in vitro (1–4).
Retroviral integration is non-random, and different
types of viruses display different preferences for chromatin
[reviewed in (5)]. Lentiviruses such as HIV-1 integrate
within transcriptionally active genes while the integration
of the gammaretrovirus Moloney murine leukemia
virus (MLV) favors the promoter regions of genes (6,7).
Other viruses, including alpharetroviruses (8,9) and
deltaretroviruses (10), show a much weaker preference
for chromatin features compared with the lentiviruses
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regions. Although the mechanisms that underlie integra-
tion site selection for most types of retroviruses are
unknown, the tendency of lentiviruses, including HIV-1,
to integrate within active genes is, in large part, determined
by the binding of the IN protein to lens epithelium-derived
growth factor (LEDGF)/p75 [reviewed in (11,12)]. The
efﬁciency of HIV-1 integration is reduced in cells depleted
for LEDGF/p75 by RNA interference (RNAi) (13,14) or
gene knockout (KO) (15–18). In the absence of LEDGF/
p75, the distribution of the residual proviruses trends away
from active genes and shows a modest shift toward
promoter regions (15,17–19). However, even in cells that
completely lack LEDGF/p75, the distribution of the
proviruses is signiﬁcantly different from random, suggest-
ingthatotherhostfactorsmightbeinvolvedindetermining
the speciﬁcity of HIV-1 integration.
LEDGF/p75 functions as a bimodal tether during
HIV-1 integration. An N-terminal PWWP domain and
two nearby copies of the AT-hook DNA-binding motif
bind chromatin (20–22) whereas the C-terminally located
IN-binding domain (IBD) binds IN (23–25). LEDGF/p75
is one of six members of the hepatoma-derived growth
factor (HDGF) related protein (HRP) family, which is
deﬁned by similarity in the sequences of the conserved
PWWP domain (23,26). One other HRP family member,
HRP2, contains an IBD that is analogous to the IBD in
LEDGF/p75 (23,24). Akin to LEDGF/p75, puriﬁed
HRP2 protein stimulates the DNA-strand transfer
activity of recombinant HIV-1 IN protein (23) and
restores integration activity to salt-depleted HIV-1 PICs
(27) in vitro, which suggests that HRP2 might play a role
in integration in infected cells. Knockdown of human
HRP2 (hHRP2) in cell lines has however failed to reveal
a role for this IN-binding factor in HIV-1 infection
(13,18,27). Co-depletion of HRP2 and LEDGF/p75 has
yielded mixed results. Human T cells that support a
minimal level of HIV-1 infection (about 3%) due to a
prior LEDGF/p75 knockdown failed to reveal a role for
HRP2 when it was subsequently knocked down (13). KO
of PSIP1, the gene that encodes LEDGF/p75, in a human
B cell line conferred an  5-fold infection defect in viral
titer, which was further reduced about 2-fold by HRP2
knockdown (18). We and others previously characterized
HIV-1 infection and integration defects using mouse
embryo ﬁbroblast (MEF) cells derived from Psip1 KO
animals (15–17,22). To analyse the role of HRP2 in
HIV-1 infection and integration under the stringent con-
dition of gene KO, we generated MEF cells from mice
disrupted for the Hdgfrp2 gene, which encodes for
HRP2, as well as Hdgfrp2/Psip1 double-KO mice, and
compared the ability of these cells to support HIV-1 inte-
gration to cells derived from littermate matched controls.
Whereas Hdgfrp2 KO cells supported normal levels of
HIV-1 infection, both viral titer and integration efﬁciency
were reduced in double-KO cells compared with single
Psip1 KO cells. The additional integration defect seen in
the double-KO cells correlated with a reduction in target-
ing to active genes and to a loss of PIC activity in vitro.
Moreover, ectopic expression of HRP2 compensated for
the loss of LEDGF/p75 function under these conditions.
An allosteric IN inhibitor (ALLINI) that targets the
LEDGF/p75 binding cleft in the dimer interface of the
IN catalytic core domain (CCD) (28,29) is signiﬁcantly
more potent when LEDGF/p75 is knocked out, effects
that are not signiﬁcantly altered by HRP2 depletion in
either wild type (WT) or Psip1 KO cells. Our results
show that HRP2 plays a role in HIV-1 PIC function
when LEDGF/p75 is absent, and rule out members of
the HRP protein family as the primary antiviral targets
of LEDGF/p75-binding site ALLINIs during integration.
MATERIALS AND METHODS
DNA constructs
The animal cell expression vector pIRES2-eGFP,
and pIRES2-hLEDGF-HA-eGFP derivative that
expresses human LEDGF/p75 [hLEDGF/p75 fused to a
C-terminal hemagglutinin (HA) tag], was previously
described (15). PCR-ampliﬁed full-length hHRP2-HA
and mHRP2-HA (see Supplementary Table S1 for a list
of primers used in this study), as well as hHRP2 lacking
the 50 end region corresponding to the PWWP domain,
were introduced into pIRES2-eGFP. The plasmid
pIRES2-hHRP2-HA-eGFP was mutagenized to change
the Asp489 GAC codon to AAC. The pGEX-
4T-1-based bacterial plasmids that express the IBDs of
hLEDGF/p75 (residues 347-471) and hHRP2 (residues
470-593) fused to the C-terminus of glutathione S-trans-
ferase (GST) were previously described (23). The corres-
ponding region of mHRP2 was PCR-ampliﬁed and
inserted into pGEX-4T-1. All PCR-ampliﬁed regions of
DNA constructs were veriﬁed by dideoxy sequencing.
Protein expression, puriﬁcation and GST pull-down assay
GST fusion proteins and His6-tagged HIV-1 IN were ex-
pressed and puriﬁed from Escherichia coli as previously
described (23,30). The conditions for the GST pull-downs
were as previously described (30).
Animal cells
HEK293T cells and primary MEFs isolated from 13.5-day
post-cotium embryos were maintained in Dulbecco’s
modiﬁed Eagle’s medium supplemented to contain 10%
fetal calf serum, 100IU/ml penicillin and 100ml/ml
streptomycin. MEF cells were transformed by expressing
the simian virus (SV) 40 large T antigen as described pre-
viously (31). Cell proliferation was quantiﬁed using the
cell titer kit from Promega.
DNA prepared from MEF cells using the QIAamp
DNA Mircro kit (Qiagen) was genotyped using primers
AE3747/AE3748, which yield a 433bp gene trap-speciﬁc
product, and AE2511/AE2512, which yield a 535bp
fragment from the third intron of the Hdgfrp2 gene; the
gene trap insertion prevents the ampliﬁcation of this latter
product (Figure 1A). Detection of WT and deleted Psip1
alleles using primers AE2331/AE2802 was described pre-
viously (15). PCR mixtures contained 100ng DNA,
0.5mM primers, 0.2mM of each dNTP, 2mM MgCl2
and 2.5U Amplitaq polymerase in buffer supplied
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12min at 95 C, reactions were cycled 30 times at 95 C
for 30s, 58 C for 30s, and 72 C for 1min. Reaction
products fractionated by electrophoresis through agarose
gels were detected by staining with ethidium bromide.
RNA extraction and quantitative (q) RT-PCR
The concentration of RNA extracted from MEF cells
using the RNeasy Mini Kit (Qiagen) was determined by
spectrophotometry. Duplicate qRT-PCR mixtures con-
tained 0.5mM primers, 1 Quantitect SYBR green
master mix, 0.3ml QuantiTect RT mix (QuantiTect Sybr
Green RT-PCR kit), and 25ng of RNA. LEDGF/p75 ex-
pression was monitored using primers AE2624/AE2625,
which target Psip1 exons 2/3 (15). Primers AE3160/
AE3161 target Hdgfrp2 exon 1/2 and downstream exon
5/7 sequences were ampliﬁed using primers AE2553/2554
(Figure 1A). Data were normalized to Ppia, which encodes
cyclophilin A, using primers AE3664/AE3665. Reactions
were incubated at 50 C for 30min and then 95 C for
15min, followed by 40 cycles of 15s at 94 C, 15s at
55 C, and 30s at 72 C. Ampliﬁcation speciﬁcity was con-
ﬁrmed by melting curve analysis from 55 Ct o9 0  C.
Viruses and infection assays
Single-round virus vectors that carry and express the
luciferase reporter gene were generated by co-transfecting
HEK293T cells with the vesicular stomatitis virus
(VSV) G expression vector pCG-VSV-G and either
pNLX.Luc.R- (HIV-Luc) or pFB-Luc (MLV-Luc) (15).
HIV-Luc was titered using an exogenous reverse
transcriptase (RT) assay. MEFs (4 10
4) seeded in
12-well plates were infected in duplicate with 10
6
RT-cpm for 8h, which corresponds to an approximate
multiplicity of infection of 0.06 (32). Cells harvested at
48h from the start of infection were processed for
luciferase activity, and results are expressed as relative
light units (RLUs) per totalmg protein in cell extracts as
determined by Bradford assay (15). For back complemen-
tation assays, E9 double-KO cells (5 10
6) were trans-
fected with 10mg DNA using MEF Nucleofector
solution 1 (Amaxa) according to the manufacturers in-
structions. Transfected cells were plated in 10cm dishes
for 24h prior to ﬂuorescence activated cell sorting to
select green ﬂuorescent protein (GFP)-positive transfect-
ants. After sorting, cells (2 10
4) were seeded in wells of a
24-well plate prior to HIV-Luc (10
6 RT-cpm) infection in
duplicate. RLU/mg values from cells transfected with
empty vector pIRES2-eGFP were subtracted from experi-
mental samples.
HIV-1 reverse transcription and integration
MEFs (3 10
5) seeded in 10cm plates were infected with
2 10
7 RT-cpm of DNase-treated HIV-Luc for 2h. Cells
were collected by typsinization, 20% were lysed for
genomic DNA extraction, and remaining cells were
plated in 4 wells of a 6-well plate for subsequent harvest
at 8, 24 and 48h from the start of infection. Three differ-
ent sets of PCR primers and probes were used to monitor
reverse transcription and integration. Primers AE2963/
AE4422 and probe AE2965 detect HIV-1 DNA late
reverse transcription (LRT) products whereas sequences
Figure 1. Hdgfrp2 KO strategy and characterization of MEF cells. (A) Shown are salient features of the pGT2lfx gene trap vector, the endogenous
and mutated Hdgfrp2 gene, the fused message that is produced in the trapped cells and the HRP2 PWWP domain fusion protein, as well as the PCR
primers that were used to monitor the gene trap allele (AE2511/AE2512 and AE3747/AE3748) and Hdgfrp2 expression levels (AE3160/AE3161 and
AE2553/AE2554). En2 SA, engrail homolog 2 splice acceptor; pA, polyadenylation signal; b-geo, fusion of b-galactosidase and neomycin transferase.
(B) QRT-PCR analysis of Hdfgrp2 expression. Exon 1/2 (gray) and exon 5/7 (black) values were normalized to the levels in+/+WT cells, with each
set to 100%. Error bars represent the variation obtained from three replicates using independent mRNA samples. (C) Western immunoblot analysis
of b-geo and mHRP2 protein expression; b-actin was probed as a loading control. Numbers to the right reﬂect migration of mass standards in kDa.
(D) Normalized luciferase values in HIV-Luc-infected+/+,+/g and g/g cell lysates. Error bars show the variation from duplicate infection, luciferase
and Bradford assays (RLU, relative light unit). Similar results were observed in three independent experiments.
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circles were ampliﬁed using primers AE4450/AE4451
and probe AE4452 (15,33–35). Duplicate reactions that
consisted of 20–30ng of DNA, 0.2mM primers, 0.1mM
probe, and 1 QuantiTect Probe PCR Master Mix were
incubated at 50 C for 2min and then 95 C for 15min,
followed by 40 cycles of 15s at 94 C, 30s at 58 C and
30s at 72 C. Serial dilutions of plasmids pNLX.luc.R-
and pUC19.2LTR in uninfected cell genomic DNA were
used to generate LRT and 2-LTR circle standard curves,
respectively (35). Integration efﬁciency was quantitated by
nested BBL-PCR essentially as previously described (15).
Duplicate ﬁrst-round PCRs ampliﬁed sequences between
integrated virus and ﬂanking genomic B1, B2 or LINE-1
using primers AE3014, AE2604, AE2605, AE2606,
AE2607, AE2608 and AE2609 (4,15). The ampliﬁcation
program was 5min at 94 C, followed by 18 cycles of
30s at 94 C, 30s at 60 C and 5min at 70 C; reactions
were terminated following a ﬁnal 10min extension at
72 C. DNA (1–2ml) was ampliﬁed in second round using
primers AE3013/AE990 and probe AE995 (4,15); the
qPCR recipe and program was the same as above. The
BBL-PCR standard curve was made by step-wise
dilution of DNA from HIV-Luc-infected WT + +/+g
cells in uninfected cell DNA. To account for plasmid
DNA carryover from transfected cell supernatants in the
infections, parallel samples were prepared in the presence
of 100mM azidothymidine, and resulting qPCR values
were subtracted from experimental samples.
For monitoring total viral DNA load over 2 weeks,
MEFs (2x 10
5) seeded in 6-well plates wells were
infected with 5 x 10
6 RT-cpm of HIV-Luc.
Western immunoblot
Whole cell lysates were used to monitor HRP2 protein
whereas LEDGF/p75 was detected in lysates of isolated
nuclei as described (15). The concentration of protein in
extracts was determined by using the Bradford assay, and
2mg of nuclear material and 10mg of whole cell extract was
fractionated by electrophoresis on sodium dodecyl sulfate
polyacrylamide gels. LEDGF/p75 was detected using
a 1:10000 dilution of rabbit antibody A300-848A-1
(Bethyl Laboratories). Afﬁnity puriﬁed rabbit antibody
generated against a peptide from the C-terminal 20
residues of mHRP2 (CQDHERTRLASESANDDNEDS)
(Bethyl Laboratories) was used at 1:5000. Ectopic expres-
sion of LEDGF/p75-HA and HRP2-HA proteins were
detected using horseradish peroxidase-conjugated anti-
HA antibody (Roche) at 1:5000. Secondary antibody
(1:10000 dilution of conjugated goat anti-rabbit; Dako
North America) was followed by detection with the ECL
prime reagent (Amersham).
PIC integration activity
PICs were isolated from cytoplasmic and nuclear extracts
of E9 cells 7h after acute infection, and in vitro integration
activity was measured by nested PCR as described
(4,15,30). Two controls were used to deﬁne assay back-
ground. First, parallel mock integration reactions
were run in the absence of the plasmid target DNA.
The ﬁrst-round PCR ampliﬁes covalently joined HIV-
plasmid sequences, so, in the second control reaction
plasmid-speciﬁc primers were omitted from parallel ﬁrst-
round reactions to control for carry over of HIV-1
sequences into the HIV-speciﬁc second-round qPCR (4).
Both control values were subtracted from experimental
samples. Resulting levels of IN-mediated DNA-strand
transfer were normalized to the total level of HIV-1
DNA in each extract.
Integration site determination
Genomic DNA isolated from MEF cells 2d after infection
was puriﬁed as indicated above. The methods used to
shear and amplify the DNA for sequencing by Illumina
were based on those described in reference (36). In brief,
DNA (5mg) was sheared into  300–500bp fragments
using adaptive focused acoustics (Covaris), and puriﬁed
using AMPure XP magnetic beads (Beckman Coulter).
The fragments were end-repaired, dA-tailed and ligated
to a double-stranded linker as instructed by the manufac-
turer. Both ﬁrst- and second-round ampliﬁcations were
multiplexed in separate tubes to increase the diversity of
the integration site libraries. DNAs were sequenced on an
Illumina GA2x machine, and results were parsed to
remove duplicate insertion sites. The integration sites
were annotated for various genomic features such as
genes, transcriptional activity, promoter regions and
CpG islands as described previously (37).
Antiviral activity assay
BI-D, a potent ALLINI that binds IN at the LEDGF/p75
binding site (28), was synthesized as described in
Supplementary Methods. E9 MEF cells (5x 10
3) seeded
in wells of a 96-well plate were infected in quadruplicate
with HIV-Luc (5x 10
5 RT-cpm) in the presence of serial
dilutions of BI-D or dimethyl sulfoxide solvent control to
determine half-maximal inhibitory concentration (IC50)
values of the drug. Luciferase activity was determined
2d post-infection.
Ethics statement
Mice were maintained at the Beth Israel Deaconess
Medical Center (BIDMC, Boston, USA) under guidelines
set forth by the USDA and US National Institutes of
Health Ofﬁce of Lab Animal Welfare. The BIDMC
IACUC approved animal protocol number 038-2012
‘Breeding LEDGF and HRP2 knockout mice’.
RESULTS
Generation of Hdgfrp2 KO mice and cells
The ability of LEDGF/p75 to support HIV-1 integration
depends critically on both the PWWP domain and IBD
(13,15,22), and both of these domains are conserved in
HRP2 (23). The amino acid sequence of mouse HRP2
(mHRP2) is 81% identical to the human ortholog and
90% similar when evolutionarily conservative substitu-
tions are considered. The amino acid sequences of the
PWWP domains of the human and mouse proteins are
Nucleic Acids Research, 2012,Vol.40, No. 22 11521identical, whereas the sequences of their IBDs are 92.7%
identical and 96.3% similar considering conservative sub-
stitutions (38) (Supplementary Figure S1A). To assess the
utility of murine cells for studies of HIV-1 infectivity, an
in vitro GST pull-down assay was used to determine the
relative binding afﬁnities of mouse and hHRP2 IBDs for
HIV-1 IN protein. As expected, the negative control GST
protein failed to pull-down a detectable level of IN
(Supplementary Figure S1B, lane 7) (23,30). Also as
anticipated, the GST-HRP2 IBD proteins pulled-down
less IN than the GST-LEDGF/p75 control protein
(18,23,24) (Supplementary Figure S1B, lanes 8–10).
Because both HRP2 IBDs recovered similar levels of
HIV-1 IN (Supplementary Figure S1C), the minor
amino acid differences in the IBDs between the human
and mouse proteins does not have a signiﬁcant impact
on IN-binding afﬁnity under these conditions.
Hdgfrp2 KO mice were generated from embryonic stem
(ES) cells obtained at BayGenomics, who use a gene trap
vector to disrupt the function of endogenous genes (39).
The pGT2lfx vector, which carries a reporter gene for the
b-galactosidase-neomycin phosphotransferase (b-geo)
fusion protein downstream from a strong splice acceptor
site and upstream from a polyadenylation signal, was
integrated between exons 3 and 4 of Hdgfrp2, which
would lead to the expression of a 1423 residue
PWWP-b-geo fusion protein (Figure 1A). Chimeric mice
generated following ES cell implantation were bred with
C57BL/6 animals, and heterozygous+/g (g for gene trap)
animals were interbred to generate WT+/+, heterozygous
+/g and homozygous g/g animals. The g/g animals survive
until adulthood and are fertile; a detailed characterization
of Hdgfrp2 and Hdgfrp2/Psip1 double-KO animals will be
presented elsewhere.
Deletion of part or all of an endogenous gene yields
genetically null phenotypes whereas gene trap KOs carry
a targeted insertion. Thus, the impact of the KO relies on
the efﬁciency of the trap (40,41). MEF cells isolated from
13.5-day post-cotium embryos were adapted for long-term
culture by transformation with SV40 large T antigen as
described (31). To assess the relative strength of the
Hdgfrp2 trap, mRNA derived from +/+, +/g and g/g
cells was monitored by qRT-PCR using primers that
amplify sequences upstream (exons 1/2) and downstream
(exons 5/7) of the insertion (Figure 1A). The levels of
upstream exonic sequences in heterozygous +/g and
homozygous g/g cells were about 57% and 33% of the
level of WT+/+cells. The level of downstream exon 5/7
sequences present in the heterozygous cells was about 44%
of the WT level whereas these sequences varied from
barely detectable to  5% of the WT in g/g cells
(Figure 1B). Hdgfrp2 expression was also analysed by
RNAseq, which yielded strikingly similar results: RNA
sequences corresponding to the upstream exons were
readily detected, but only very low levels of RNA corres-
ponding to the downstream exons were present in g/g cells
(data not shown). The predicted 161kDa PWWP-b-geo
fusion protein was readily detected by western blotting
+/g and g/g cell extracts. As expected from the
qRT-PCR analysis, g/g cells did not contain a detectable
level of mHRP2 protein (Figure 1C).
Hdgfrp2 KO cells support normal levels of
HIV-1 infection
To assess the role of HRP2 protein in HIV-1 infection,
MEF cells were infected with a single-round HIV-1 vector
that carries and expresses the gene for ﬁreﬂy luciferase
(HIV-Luc). Two days post-infection, levels of luciferase
activity were normalized to the total protein content in
the cell extracts. Each cell type supported similar levels
of luciferase activity (Figure 1D). Therefore, HRP2 does
not play an essential role in HIV-1 infection under these
experimental conditions.
Generation and characterization of MEFs from
Hdgfrp2/Psip1 double-KO animals
Our ﬁndings with Hdgfrp2 g/g cells are consistent with
previous reports that failed to detect a role for HRP2 in
HIV-1 infection using RNAi (13,18,27). We next sought to
determine if removing LEDGF/p75 might reveal a pheno-
type for the HRP2 KO. Because Hdgfrp2-disrupted cells
support efﬁcient infection (Figure 1D) and adult g/g
animals are fertile, heterozygous + /+g animals were
interbred with + /gg animals. The latter mice, which
are heterozygous for Psip1 KO but homozygous for the
Hdgfrp2 gene trap, were used to increase the odds of ob-
taining the desired WT and single- and double-KO
embryos from the same litter. All of the mice that
resulted from this breeding scheme carried at least one
gene trap allele: WT, + +/+g; HRP2 KO, + +/gg;
LEDGF/p75 KO,   /+g; double KO,   /gg. The term
‘WT’, in the context of the double KO, accordingly refers
to heterozygous +/g animals. Pregnant females were dis-
sected at day 13.5 post-cotium until two complete sets of
matched embryos were obtained (denoted E9 and E13;
Supplementary Figure S2). Expression proﬁling conﬁrmed
the different KO phenotypes among the cell types from
each set of embryos. The growth rates of the single- and
double-KO cells from each set were similar to the matched
WT cells (Supplementary Figure S2 and data not shown).
Both sets of cells were infected with HIV-Luc, and
luciferase activities in cell extracts were determined as
above. As expected from Figure 1D, each Hdgfrp2 KO
cell line supported a similar level of HIV-Luc infection
as the matched WT control (Figure 2A and B). The
Psip1 KO cells from the E13 set supported about 21%
of the level of infection observed with the matched + +/
+g cells whereas the E9 Psip1 KO supported about 11%
of the matched control. In both cases, the addition of the
Hdgfrp2 KO reduced infectivity about 2-fold, with the E13
and E9 double-KO cells supporting about 11.3% and
5.9% of the level of the matched infection with the re-
spective WT control cells (Figure 2A and B). In both
cases, the difference between Psip1 KO and double-KO
cells was statistically signiﬁcant.
Cells were also challenged with two control viruses.
Infections with N/N-Luc, which carries two inactivating
mutations (D64N/D116N) in the IN active site, results in
low levels of luciferase activity despite the absence of IN
activity due to inefﬁcient cell-mediated DNA recombin-
ation and/or transcription from unintegrated DNA tem-
plates (42,43). The various cells from the E9 set each
11522 Nucleic Acids Research, 2012,Vol.40, No. 22supported similar levels of N/N-Luc activity, which varied
from about 0.09% to 0.14% of the level of HIV-Luc
expression in WT + +/+g cells. Based on these results,
we conclude that the different levels of HIV-Luc infection
across the various cell types depended on functional IN
activity and that the double-KO cells support a residual
level of HIV-Luc integration that is, based on comparative
HIV-Luc and N/N-Luc titers, minimally 40-fold over
background. MLV-Luc was used as a positive control
virus. MLV IN does not bind LEDGF/p75 (44,45) and
as expected, MLV-Luc infected the different cell types at
a similar efﬁciency (Figure 2C).
HRP2 KO causes an integration defect in
LEDGF/p75 KO cells
Psip1 KO cells support normal levels of HIV-1 reverse
transcription but reduced levels of virus integration
(15,17,18). To investigate the cause of the additional
defect in infection seen in Hdgfrp2/Psip1 double-KO
cells, DNA synthesis, nuclear migration and integration
were monitored by qPCR using three sets of primers/
probes. Viral R and gag-speciﬁc primers yield products
that reﬂect the total viral DNA synthesized, whereas
U5 and U3 primers amplify 2-LTR circles that form in
the nucleus through the action of non-homologous end-
joining machinery (34). Integration in human cells is
often measured using PCR anchored through the repeti-
tive Alu element. Because Alu is a primate-speciﬁc repeat,
our mouse cell integration assay uses the B1, B2 and
LINE-1 repeat sequences (BBL-PCR) (15). IN inhibitors
or inactivating IN mutations quantitatively block inte-
gration and increase the proportion of linear viral
DNA molecules available for circularization in the
nucleus. An increase in the amount of 2-LTR circles is
therefore indicative of failed integration (35,46).
The level of viral DNA synthesis, which peaked at 8h
post-infection and diminished thereafter, was similar
across the 4 different cell types (Figure 3A). As
expected, the level of HIV-1 integration in WT and
Hdgfrp2 KO cells was similar at 2 days post-infection
(Figure 3B). Also as expected, integration in Psip1 KO
cells was reduced compared with the WT cells, by about
2.5-fold in these assays. Because integration in double-
KO cells was further reduced (to about 10% of the level
in WT cells), we conclude that a lower level of integration
underlies the reduced level of infection by the HIV-Luc
vector in the double KO as compared with Psip1 KO
cells. This interpretation is supported by two additional
observations. Consistent with an integration defect, the
level of 2-LTR circles in Psip1 KO cells was about
2.5-fold higher than in WT cells at 24h post-infection
(Figure 3C) (13–15). A further increase in the level of
2-LTR circles, which amounted to approximately a
5-fold increase over that observed in WT cells, was seen
in the Psip1/Hdgfrp2 double-KO cells, which is consistent
with the decreased level of integration. Secondly, total
viral load was proﬁled over a 2-week time course.
Because unintegrated viral DNA is not replicated, it is
diluted in cultures of dividing cells (34). Experiments that
use HIV-based vectors to knockdown host factors have
taken advantage of the decay in unintegrated viral DNA
over time to gauge the relative integration levels in subse-
quent viral challenges (13,17). The total level of HIV-1
DNA in WT and Hdgfrp2 KO cells was similar at 2
weeks post-infection. However, the levels in Psip1 and
Psip1/Hdgfrp2 KO cells were  25% and 12% of the
level in WT cells, respectively (Figure 3D). Thus, the efﬁ-
ciency of viral DNA integration correlates with relative
level of HIV-1 infection in the four cell types (Figures 2
and 3).
The integration defect in Psip1/Hdgfrp2 KO cells
correlates with PIC activity
We previously determined that HIV-1 PICs made in Psip1
KO cells are fully competent to integrate the viral reverse
transcript in vitro (15). To determine if the remaining
HRP2 in these cells might inﬂuence PIC function, cyto-
plasmic and nuclear material extracted from cells 7h from
the start of infection were incubated with plasmid target
DNA in the presence of Mg
2+ ions. Puriﬁed DNAs were
examined by nested qPCR to detect the formation of
covalent HIV-plasmid DNA junctions, and these values
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Figure 2. HIV-1 but not MLV is defective for infection of Hdgfrp2/
Psip1 double-KO cells. (A) Normalized levels of HIV-Luc infection of
littermate control sets of E13 cells. Plotted are averages and standard
deviations from pooled independent sets of experiments (n=6), with
the level of WT + +/+g RLU/mg set to 100%. (B) Similar to panel A,
except the E9 set of cells was analysed in n=5 experiments.
(C) MLV-Luc titers on the indicated E9 cell lines for n=2 independent
experiments. n.s., not signiﬁcant; *P<0.05; **P<0.01 as determined
by one-tailed Student’s t-test.
Nucleic Acids Research, 2012,Vol.40, No. 22 11523were normalized to the total level of HIV-Luc DNA in the
extracts. As expected, PICs extracted from Psip1 KO cells
showed levels of integration activity similar to PICs ex-
tracted from WT and Hdgfrp2 KO cells (Figure 4). PICs
extracted from double-KO cells supported about half this
level of activity, linking the drop in chromosomal integra-
tion in double-KO cells to a reduction in the strand
transfer activity of PIC-associated IN.
Differential effects of Psip1 and Hdgfrp2 KO on
integration site distribution
In addition to inﬂuencing the overall efﬁciency of integra-
tion, LEDGF/p75 in large part determines the propensity
for HIV-1 to integrate within the bodies of active genes
(15,17–19). To ask whether HRP2 KO might also contrib-
ute to integration targeting, high molecular weight DNA
isolated 2 days after infection was sheared, end-repaired,
ampliﬁed by ligation-mediated PCR and sequenced by
Illumina to determine the genomic sites of HIV-1 DNA
integration. The integration datasets, which were initially
parsed to remove duplicate sequences, were analysed for
numerous genomic features including genes, gene density
and areas nearby transcription start sites (TSSs) and CpG
islands (Table 1; see Figure 5 for corresponding statistical
analyses). The data presented here are from the E13 set of
MEF cells; similar results were obtained using the E9 cell
set (data not shown).
In agreement with prior ﬁndings (15,17–19), the
LEDGF/p75 KO signiﬁcantly reduced the frequency of
integration within transcription units (from 68.9% to
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11524 Nucleic Acids Research, 2012,Vol.40, No. 2243.5%), with concomitant increases in integrations near
TSSs and CpG islands. We also note that integration
into gene dense regions was signiﬁcantly reduced in cells
lacking LEDGF/p75. Though this result differs from prior
published reports (17,47), it is reproducibly observed in
relatively large data sets of integrations in Psip1 KO
cells (Y. Koh et al., submitted for publication). As
expected, the LEDGF/p75 KO also signiﬁcantly altered
the ability of HIV-1 to integrate into active genes
(Figure 6). With the exception of integration nearby
CpG islands, which likely attained a modest signiﬁcance
due to our large datasets (P=0.037), the Hdgfrp2 KO did
not signiﬁcantly impact the frequencies at which HIV-1
targets mouse genomic features (Table 1; Figures 5
and 6). Compared with the Psip1 KO alone, adding the
Hdgfrp2 KO signiﬁcantly reduced the frequency at which
HIV-1 integration targeted active genes, although integra-
tion into gene dense regions and nearby TSSs and CpG
islands was not signiﬁcantly affected (Table 1; Figures 5
and 6). HRP2 therefore contributes to the targeting of
HIV-1 PICs to active genes, a result that is revealed
when the dominant IN-binding protein, LEDGF/p75, is
absent from the cell.
HIV-1 integration is modestly inﬂuenced by the nucleo-
tide sequence at the site of insertion (10,48), a trait that is
not signiﬁcantly altered by Psip1 KO (15,17,18). The se-
quences listed in Table 1 were queried to determine if dual
depletion of HRP2 and LEDGF/p75 might inﬂuence local
sequence preference during integration. This analysis
revealed that the preferred target DNA integration
sequence TDG#GTWACCHA (# indicates the position
of plus-strand joining) (10,48) was not affected by the
presence or absence of either LEDGF/p75 or HRP2
(Supplementary Figure S3).
Ectopic LEDGF/p75 or HRP2 expression restores HIV-1
titer and integration speciﬁcity to double-KO cells
Expressing hLEDGF/p75 in Psip1 KO MEFs restores
HIV-1 infectivity (15). To determine whether HRP2
might also function under these conditions, double-KO
cells transfected with vectors that express both the
protein of interest and GFP were sorted for GFP expres-
sion, plated and challenged with HIV-Luc (15). Two days
later, levels of HIV-Luc infectivity (Figure 7) and genomic
sites of HIV-1 integration (Table 1) were determined.
Expression of hHRP2 or mHRP2 stimulated HIV-Luc in-
fection to about 60% and 34% of the level observed with
hLEDGF/p75, respectively (Figure 7). Two different
hHRP2 mutants were tested for their ability to rescue
HIV-1 integration and infection. In one mutant, the
N-terminal PWWP domain was deleted; in the other, the
Asp residue that corresponds to Asp366 in the LEDGF/
p75 IBD, which makes critical H-bond contacts with the
backbone amides of IN (49), was substituted by Asn
(D489N). Neither of these mutants increased the level of
HIV-Luc infection above the background seen with the
empty vector in pIRES2-eGFP transfected cells. We there-
fore conclude that HRP2 rescue of HIV-1 infection
requires both the speciﬁc interactions with IN provided
by the IBD, and with chromatin provided by the PWWP
domain. Accordingly, expression of either hHRP2 or
hLEDGF/p75 was able to restore, in large part, the
normal proﬁle of integration targeting in the double-KO
cells, although the effect of hHRP2 on integration nearby
TSSs and CpG islands was somewhat more modest than
that of hLEDGF/p75 (Table 1).
Contribution of LEDGF/p75 and HRP2 to the antiviral
activity of a potent ALLINI
Different approaches have been used to identify antiviral
compounds that engage IN at the LEDGF/p75 binding
site. One approach depended on detecting a perturbation
of host factor-IN binding (50) whereas a separate ef-
fort screened for inhibitors of IN 30 processing activity
(28,51). In addition to blocking the LEDGF/p75-IN inter-
action, it has recently become clear that these compounds
inhibit the assembly of the stable synaptic IN-viral
DNA complex and thus affect IN activity in a
LEDGFp75-independent manner in vitro (51–53). The
compounds also remain active in PSIP1 KO cells, suggest-
ing that their ability to disrupt the HRP2-IN interaction
could contribute to their antiviral activity (18). Our novel
MEF cell lines presented an excellent opportunity to de-
termine the contribution of LEDGF/p75 and HRP2 to the
antiviral activity of ALLINIs. BI-D, a representative of
this class of inhibitors (28), was synthesized as described in
Supplementary Methods. The IC50 of the BI-D inhibitor
was determined during the acute phase of HIV-1 infection,
at the time LEDGF/p75 and HRP2 are known to
function. Approximately 2.4–2.9mM of BI-D was
required to inhibit 50% of HIV-Luc infection of WT
and Hdgfrp2 KO cells, while the IC50 decreased dramat-
ically, to 160–200nM, in Psip1 and double-KO cells.
Table 1. Integration site usage among cell type
Annotation Random WT MEFs HRP2 KO LEDGF KO Double KO Double
KO+hHRP2
Double
KO+hLEDGF
Unique integrations 100000 381429 146243 130867 80483 62657 134169
Within a gene 33031 (33.0%) 262774 (68.9%) 100453 (68.7%) 56894 (43.5%) 32199 (40.0%) 41194 (65.8%) 87142 (65.0%)
+/  1 kB of a TSS 1595 (1.60%) 2104 (0.55%) 747 (0.51%) 4652 (3.55%) 2852 (3.54%) 974 (1.55%) 1023 (0.76%)
+/  1 kB of a CpG
island
728 (0.73%) 1334 (0.35%) 460 (0.31%) 2800 (2.14%) 1667 (2.07%) 767 (1.22%) 634 (0.47%)
Avg. genes per Mb 8.5 14.0 14.2 10.7 10.8 15.0 13.3
Refseq genes from mouse genome build mm9, UCSC Genome Bioinformatics website.
Nucleic Acids Research, 2012,Vol.40, No. 22 11525In contrast, the IC50 value for the IN active site inhibitor
raltegravir was similar in each cell type (Table 2).
DISCUSSION
To address the roles of LEDGF/p75 and HRP2 in HIV-1
infection and integration, we developed littermate-
matched cell lines knocked out for each of these factors,
as well as double-KO cell lines that lack both factors.
While targeted deletion was used to KO Psip1 (15),
Hdgfrp2 was disrupted by insertion of the pGT2lfx gene
trap vector. The position of vector integration can inﬂu-
ence the efﬁciency of a trap (40), and expression proﬁling
by both qRT-PCR (Figure 1B and Supplementary Figure
S2B) and RNAseq (data not shown) indicated that down-
stream exonic sequences could be expressed in homozy-
gous g/g cells at relatively low levels (up to 5% of the level
observed in WT cells). Although we were unable to detect
a corresponding level mHPR2 protein by western blotting,
we cannot dismiss the possibility that a low level of func-
tional mHRP2 persists in g/g or Psip1/Hdgfrp2 KO cells.
Gene trap insertion was previously used to disrupt Psip1
expression and, similar to the results reported here, a low
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Figure 5. Statistical analysis of integration site targeting frequencies among cell type. Pairwise comparisons of the indicated Table 1 datasets were
analysed using Fisher’s exact test to determine statistical signiﬁcance of HIV-1 integration within genes as well as nearby transcriptional start sites
and CpG islands. Integration into gene dense regions of chromosomes, expressed as average number of genes per Mb, was analysed by Mann–
Whitney rank sum test. P-values>0.05 are highlighted in bold italics.
Figure 6. Integration as a function of gene expression. Refseq genes
are sorted by expression along the x-axis from high to low in bins of
100 genes each. Integration sites within genes in each bin were counted
and normalized by the size of the bin and the total number of integra-
tion sites (per Mb region/10000 sites). Paired Wilcoxon matched t-test
analysis revealed the following statistically relevant (P<0.0001) com-
parisons: WT versus LEDGF KO; WT versus double KO; LEDGF
KO versus HRP2 KO; LEDGF KO versus double KO; HRP2 KO
versus double KO; and WT, LEDGF KO, HRP2 KO, double KO
versus random. In contrast, the WT and HRP2 KO proﬁles did not
differ signiﬁcantly from one another (P=0.9992).
11526 Nucleic Acids Research, 2012,Vol.40, No. 22level of Psip1 message was read through that trap (16).
Because Psip1 KO cells produced by gene trap insertion
and chromosomal deletion behave indistinguishably in
assays for HIV-1 infection and integration (15,17), we
infer that if there is a low level of mHRP2 protein in
homozygous g/g cells, it is unlikely to have a signiﬁcant
impact on the efﬁciency or speciﬁcity of HIV-1
integration.
Although mouse cells present numerous blocks to
HIV-1 replication (54), they are efﬁciently transduced by
pseudovirions, a trait that we and others have used to
study the roles of host factors in the early stages of
HIV-1 infection (15,17,31,55–57). The PWWP domains
of hHRP2 and mHRP2 are identical, and the minor
amino acid variation between these IBDs does not have
an obvious impact on HIV-1 IN-binding afﬁnity
(Supplementary Figure S1). Hence, mouse cells afford a
convenient model for studying the roles of both LEDGF/
p75 and HRP2 in HIV-1 integration. By extension, these
cells are useful reagents to investigate the roles of
LEDGF/p75-IN and HRP2-IN interactions in the anti-
viral activities of ALLINIs that target the host
factor-binding site at the IN CCD dimer interface.
HRP2 and HIV-1 integration
HIV-1 infection and integration site distribution were
largely unaffected by the HRP2 KO. It is important to
appreciate the fact that early attempts to knockdown
LEDGF/p75 expression using RNAi failed to reveal a
role for the protein in HIV-1 infection despite achieving
potent reductions in the steady-state level of the host
factor (27,44). These conditions nevertheless altered the
speciﬁcity of integration (19), showing that the minute
amounts of LEDGF/p75 that are sufﬁcient to support
normal levels of HIV-1 infection nevertheless fail to
sustain the speciﬁcity of PIC/integration targeting.
Subsequently, more stringent knockdowns and LEDGF/
p75 KOs revealed the central role of this host factor-in
mediating both the efﬁciency and speciﬁcity of HIV-1 in-
tegration (13,15,17,18). The fact that the Hdgfrp2 KO
does not affect HIV-1 targeting of genomic features
argues against a signiﬁcant role for this secondary IN-
binding protein in determining the distribution of HIV-1
integration in cells that express LEDGF/p75. This result
clariﬁes the dominant role of LEDGF/p75 as the key
IN-binding integration co-factor during the early phase
of HIV-1 infection. A signiﬁcant subsidiary role for
HRP2 in HIV-1 integration was revealed by comparing
the behavior of the virus in cells knocked out for
LEDGF/p75 to cells depleted for both host factors.
These data revealed that, under the right conditions,
HRP2 could inﬂuence HIV-1 PIC activity, which
correlated with an  2-fold reduction in chromosomal
DNA integration and loss of targeting to active genes
(Figures 5 and 6; Table 1). Although the mechanistic
basis for the role of the host factors in PIC function is
unclear, models based on the stimulation of IN activity
and/or target DNA binding can be considered. LEDGF/
p75 and HRP2 each stimulate the DNA-strand transfer
activity of HIV-1 IN in vitro (23), suggesting that
factor-mediated tetramerization of the enzyme (58,59)
might play an important role in PIC function. LEDGF/
p75 binds DNA non-speciﬁcally (21) and although we
have not assessed HRP2 DNA-binding activity, the
protein harbors sequences similar to the AT-hook DNA-
binding motifs in LEDGF/p75 (23), suggesting that it
might also engage DNA non-speciﬁcally. Additional
work with LEDGF/p75 and HRP2 mutant proteins that
disrupt DNA and/or IN binding is necessary to further
investigate these possibilities. Because double-KO cells
support integration at levels signiﬁcantly above back-
ground, we conclude that IN and/or other host factors
can contribute to gene targeting during HIV-1 infection
in the absence of both HRP2 and LEDGF/p75 (Table 1
and Figure 6).
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Figure 7. Ectopic LEDGF/p75 and HRP2 expression each restore
HIV-1 infection to double-KO cells. Shown are RLU/mg values
normalized to the level of infection of LEDGF/p75-expressing cells,
which was set to 100%. Error bars are the variation obtained from
duplicate conditions (infection, luciferase and Bradford assays). Lower
panels, immunoblot of hHRP2 (lane 2), hLEDGF/p75 (lane 3),
hHRP2PWWP (lane 4), hHRP2/D489N (lane 5) and mHRP2 (lane
6) expressing cells; the extract loaded in lane 1 came from cells trans-
fected with the empty vector. Results are representative of those
observed in two independent experiments.
Table 2. Raltegravir and BI-D IC50 values
WT + +/+g HRP2
KO + +/gg
LEDGF
KO   /+g
Double
KO   /gg
Raltegravir
IC50 (nM)
4.0±1.5 3.2±1.2 5.6±1.0 4.8±2.9
BI-D IC50 (mM) 2.9±1.5 2.4±1.0 0.16±0.09 0.20±0.09
Mean±standard deviation for n=4 independent experiments.
BI-D IC50 value statistics (Student’s t-test): WT versus HRP2 KO, n.s.;
LEDGF KO versus WT, P<0.05; double KO versus LEDGF KO,
n.s.; WT and HRP2 KO versus LEDGF KO and double KO,
P<0.001.
Nucleic Acids Research, 2012,Vol.40, No. 22 11527LEDGF/p75 functions as a bimodal tether during inte-
gration: elements in the N-terminal portion of the protein
bind to chromatin whereas the downstream IBD binds IN.
The viral side of the equation is well understood:
co-crystal structures have revealed intimate contacts
between the IBD and the CCD dimer interface and a1
of the N-terminal domain of IN (49,60), results that
have been conﬁrmed by numerous biochemical and
genetic experiments (13,15,38,60). The binding of HRP2
to IN is likely weaker than the corresponding interaction
with LEDGF/p75 because of two conservative substitu-
tions at critical IBD contact residues: LEDGF/p75
residues Ile365 and Phe406 are replaced by Vall488 and
Tyr529, respectively, in HRP2 (38). The cellular side of the
bimodal tether is less well understood. Both LEDGF/p75
and HRP2 are nuclear proteins, but only LEDGF/p75
behaves as a constitutive component of chromatin (24).
Nevertheless, HRP2 can direct HIV-1 DNA integration
to active genes in the absence of LEDGF/p75 (Figure 6
and Table 1), and it functions efﬁciently as a co-factor for
HIV-1 infection and integration when it is ectopically ex-
pressed in double-KO cells. As expected, this rescue of
infectivity depends on the N-terminal PWWP domain of
HRP2 (Figure 7). These results suggest that HRP2 can
interact with chromatin when LEDGF/p75 is depleted
from cells. A more detailed understanding of the roles of
LEDGF/p75 and HRP2 in HIV-1 integration will come
from deciphering the mechanism(s) of the interactions of
these PWWP domains with chromatin. It will also be in-
structive to test whether HRP2 plays a role in physiolo-
gically relevant targets of HIV-1 infection, such as
monocyte-derived macrophages, that express relatively
low levels of LEDGF/p75 protein (17).
Mechanism of action of ALLINIs
Several groups have described similar 2-(quinolin-3-yl)-
acetic acid derivatives that inhibit LEDGF/p75-IN
binding in vitro and integration during the acute phase
of HIV-1 infection (50–53). Initially dubbed LEDGINs
(LEDGF/p75-IN inhibitors), it has recently become
apparent that these compounds inhibit the assembly of
IN on viral DNA (51–53), a step that in all likelihood
precedes the binding of LEDGF/p75 to IN during
HIV-1 infection (61,62). Accordingly, the drugs inhibit
IN catalytic function in vitro in a LEDGF/p75 independ-
ent manner (51–53). We therefore refer to these com-
pounds as ALLINIs or ‘allosteric IN inhibitors’ to
emphasize their host factor-independent mode of action.
ALLINIs nevertheless reveal steep dose response curves in
antiviral activity assays, indicating inhibition of a func-
tionally multivalent target (51,63). Based on the available
in vitro data, potential ALLINI targets during HIV-1
infection include assembly of the stable synaptic IN-viral
DNA complex and the interaction of the assembled PIC
with LEDGF/p75 (51–53). LEDGINs were recently
shown to retain activity in PSIP1 KO cells, suggesting
that inhibiting the interaction of HRP2 with IN
might be an important target under these conditions (18).
We show here that this is unlikely to be the case. The
antiviral activity (IC50) of the ALLINI inhibitor BI-D
increased signiﬁcantly, from about 2.9mM in WT cells to
0.16mMi nPsip1 KO cells, a result that was not signiﬁ-
cantly altered by Hdgfrp2 disruption (Table 2). Our results
suggest that LEDGF/p75 competes with the inhibitors for
binding at the IN CCD interface during infection, and
that HRP2 is less able to compete with the inhibitor
because it binds to IN more weakly than LEDGF/p75.
If the interactions with IN were the important antiviral
targets of the ALLINI inhibitor, we would have
expected the IC50 to increase in the absence of the key
interacting factors, which is not the case.
We and others have observed that HIV-1 produced in
the presence of ALLINIs is non-infectious (K. A. Jurado,
unpublished observation) (53). The IC50 of BI-D in an
assay which measures the spread of HIV-1NL4-3 in
human T cells (51) is  100nM (unpublished observa-
tions). Because the LEDGF/p75-IN interaction is not
thought to play a post-integration role in HIV-1 replica-
tion (64), our data indicate that ALLINIs act primarily
by engaging IN during virus production to inhibit the
subsequent round of stable synaptic IN-viral DNA
complex assembly. The strength of the inhibitor is accord-
ingly increased during the early stage of HIV-1 replication
when LEDGF/p75 is removed from the system (Table 2),
implying that LEDGF/p75 normally engages the PIC
soon after IN assembles on the viral DNA (44,65). Our
single- and double-KO cells should continue to be
valuable agents to investigate LEDGF/p75 function
during HIV-1 infection and the multimode mechanism
of action of clinically relevant ALLINIs.
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